Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 2 diabetes~2. HbA1c \> 6.5%~3. age \> 18 years~4. male and females~Exclusion Criteria:~1. age \> 75 years~2. HbA1c \> 10 %,~3. reduced renal function (eGFR \< 60 ml/min/1.73 m²).~4. insulin therapy, or any antidiabetic medication other than metformin.~5. uncontrolled hypertension (\> 180/\>110 mmHg)~6. cardiovascular event within the last 3 months~7. Use of loop diuretics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: ACTIVE_COMPARATOR): Dapagliflozin, 10 mg/day, oral administration, 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, oral administration, 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).